Dyslipidemia Therapeutics Market | Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, and Novartis AG.

Consolidation of Multinationals Continues, With Nearly 60% Shares

Nature of the global dyslipidemia therapeutics market remains consolidated, with leading players accounting for approximately 60% shares. Co-promotion of dyslipidemia therapeutic drugs with local or regional players, aggressive marketing, new product launches, and high investments in research and development of novel drugs are the go-to strategies being employed by leading dyslipidemia therapeutics market players to expand their global footprint. Meanwhile, local players continue to focus on expanding their manufacturing capacity to meet the growing demand for dyslipidemia drugs in the regional market. Additionally patent expiration of a multiple dyslipidemia drugs is expected to open up new opportunities for the regional players in terms of drug discovery and development. Some of the notable highlights of the dyslipidemia therapeutics market have been listed below:

Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2928

To capitalize on the growing demand for dyslipidemia drugs in the Chinese market, AstraZeneca entered into a strategic alliance with Luye Pharma that bestowed the company with exclusive rights to promote Lyue Pharma’s Xuezhikang Capsules - a drug that has been identified as the first-line blood management medication by the Chinese government.
As a part of its marketing strategy, Kowa Pharmaceuticals America, Inc. launched the “Take Cholesterol to Heart” campaign, to promote the efficacy of statins in the treatment of dyslipidemia. The company is partnering with Hollywood stars and TV actors for the campaign.
Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work towards inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs).
In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.
Recent research has linked the presence of high levels of lipoprotein (a) cholesterol (Lp[a]-C), and low levels of lipoprotein cholesterol subparticle 3 (HDL3C), identifying these as novel biomarkers to diagnose the severity of coronary artery disease (CAD) in patients. The results have the potential to drive advancements in the dyslipidemia therapeutics market.
The report on the dyslipidemia therapeutics market also provides a detailed analysis of the key players operating in the dyslipidemia therapeutics market. The dyslipidemia therapeutics market report provides a comprehensive profile of leading players functioning in the dyslipidemia therapeutics market which include Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, and Novartis AG.

Browse Full Report @ https://www.factmr.com/report/2928/dyslipidemia-therapeutics-market

Efficacy-driven Novel Approaches for Dyslipidemia Therapeutics

Combination therapies for dyslipidemia have gained a marked significance in the recent past, deemed as an efficient solution to offset concerns regarding varied effectiveness of statins with respect to affected patients. Complementary mechanisms in combination with statins have emerged as a novel measures to ebb low-density lipoprotein levels – a key aspect enhancing the risk of dyslipidemia. Recent approval of novel drugs such as PCSK9 antibodies by regulatory authorities such as China’s National Medical Products Administration (NMPA), and The UK’s National Institute for Health and Care Excellence (NICE), alludes a rise in prevalence of novel drugs for dyslipidemia therapeutics in the near future. Medical researchers’ efforts towards the identification of new gene therapies for treatment of Mendelian lipid disorders can further open gateways to efficient dyslipidemia therapeutics and management. Additionally, leading players in the dyslipidemia therapeutics market are taking efforts to improve the overall efficacy of their dyslipidemia therapeutic drugs and are investing heavily in research and development of novel medication to target triglycerides and other lipoproteins.

Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=2928

Opportunities Imminent for Players, as Use of Nutraceuticals in Dyslipidemia Therapeutics Gains Significance

Shifting consumer preference towards using nutraceuticals to combat health concerns has triggered multiple researches on effectiveness of nutraceuticals in reducing lipid levels in patients. Statin intolerance is a common occurrence in patients, and nutraceuticals provide a natural alternative to keep lipids in check. Consumption of statins has been linked with certain side effects that has significantly raised concerns regarding statins among healthcare professionals and patients alike. New-onset diabetes, muscle pain, and increased incidences of hemorrhagic stroke have been reported among patients consuming statins. Nutraceuticals such has omega-3 fatty acids, soy proteins, spirulina, lupin, berberine, red yeast rice, and garlic fibers are some of the functional foods that have cholesterol-lowering benefits. Although the degree of their effectiveness on different patients is not yet fully understood, nutraceuticals are likely to gain significance as a natural treatment with no adverse effects on patients.

Collaborative and Integrated Efforts towards Drug Development to be a Key Growth Influencer

With growth palpability in patent expiration of multiple exclusive dyslipidemia therapeutic drug, pharmaceutical companies are continuously striving towards developing new and innovative solutions. However, certain factors such as lower pricing pressures, and early access to new and innovative therapies, have exacerbated the difficulties in drug development for dyslipidemia therapeutics. This has further resulted in a significant imbalance between R&D investments and profits related to dyslipidemia therapeutics.

Pharmaceutical companies are already following strategies such as open innovation, in-and-out licensing, and active technology scouting to boost innovation in dyslipidemia therapeutics development. Additionally, agency partners that offer a multidisciplinary and integrated approach for drug development will continue to sustain growth of the dyslipidemia therapeutics market. With expertise across disciplines, the agency partners could provide a solution to streamline the process of new drug development and marketing thus simplifying the drug development process for pharmaceutical companies.

Government Initiatives Aimed at Dyslipidemia Awareness to Uphold Growth

According to a report by the World Health Organization (WHO) ischemic heart diseases were identified as the leading cause of deaths around the world, accounting for 15.2 million deaths in 2016. Dyslipidemia has been associated with significant risk of ischemic heart diseases, strokes, heart attacks, and other cardiovascular conditions. Another report from WHO stated that dyslipidemia was responsible for causing 2.6 million deaths and 29.7 million disability adjusted life years. The adverse impact of the condition has prompted governments to initiate awareness campaigns and provide a proliferating environment for the development and approval of dyslipidemia therapeutics. For instance, the American College of Cardiology and American Heart Association released updated guidelines on cholesterol in November 2018 educating the population about personalized risk assessments of higher cholesterol levels and listed a set of recommended dyslipidemia therapeutic drugs. Along the same lines, UK Health Ministry ordered the rapid uptake of the newly discovered PCSK9 inhibitors with an aim to enable the beneficial treatment to reach patients quickly. The amiable environment created by regulatory authorities around the world is expected to fuel the dyslipidemia therapeutics market growth.

Dyslipidemia Therapeutics Market - Definition

Dyslipidemia is a condition caused due to the presence of an abnormal amount of lipids such as triglycerides, fat phospholipids, and cholesterol in the blood. The presence of these lipids increases the chances of stroke, heart attacks, atherosclerosis, and other circulatory problems. Therapies and drugs used in the treatment of dyslipidemia are termed as dyslipidemia therapeutics which includes drugs such as statins, non-statins, fibrates, inhibitors, and bile acid resins.

Dyslipidemia Therapeutics Market - About the report

The report on dyslipidemia therapeutics market offers comprehensive insights into the dyslipidemia therapeutics market. The FactMR dyslipidemia market report provides a thorough assessment of the dyslipidemia market facets such as drivers, restraints, trends, opportunities, challenges, and threats.

The dyslipidemia therapeutics market report provides an accurate forecast of the dyslipidemia therapeutics market which is meant to aid stakeholders and business professionals in streamlining their strategies to obtain maximum profitability.

Dyslipidemia Therapeutics Market – Segmentation

The dyslipidemia therapeutics market report offers a detailed analysis of the dyslipidemia market on the basis of different segments. A comprehensive analysis of each of the dyslipidemia therapeutics market segments on the basis of value, Y-o-Y growth, revenue share, and CAGR has been provided in the report.

Dyslipidemia Therapeutics Market – Additional Questions Answered

Apart from the aforementioned insights about the dyslipidemia therapeutics market, the report answers the following questions related to dyslipidemia therapeutics market:

What region will hold the largest share of the dyslipidemia therapeutics market in 2019?
What dyslipidemia drug type currently holds the pole position in terms of revenue?
What dyslipidemia drug class will register the highest sales in 2019?
What sales channel accounted for the most dyslipidemia therapeutic drug sales in 2018?
What are the lucrative opportunities on offer in the dyslipidemia therapeutics market?
Dyslipidemia Therapeutics Market – Research Methodology

The key insights propounded in the dyslipidemia therapeutics market report are a consequence of thorough research. A comprehensive two-step research process was employed to survey all the aspects pertaining to the dyslipidemia therapeutics market. The report on dyslipidemia therapeutics market is a combination of detailed primary and secondary researches performed by the analysts at Fact.MR.

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/

Read Industrial News : https://theswisstimes.com/

This release was published on openPR.